Neutrophil-to-Lymphocyte Ratio and Outcomes in Patients Admitted for Acute Heart Failure (As Seen in the BLAST-AHF, Pre-RELAX-AHF, and RELAX-AHF Studies)
Section snippets
Methods
An analysis was conducted from the pooled data from the BLAST-AHF, Pre-RELAX-AHF, and RELAX-AHF randomized, placebo-controlled studies for patients with acute HF. All studies were approved by local ethics committees and conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from each patient who participated in these studies.
The methods and main results of BLAST-AHF (NCT01966601), Pre-RELAX-AHF (NCT00520806), and RELAX-AHF (NCT00520806) were published
Results
Baseline characteristics by NLR tertile at randomization are presented in Table 1. Overall, higher NLR was significantly associated with older age, White race, lower weight, lower body mass index, hypertension, more severe dyspnea by VAS, higher heart rate, and higher respiratory rate. There were also significant differences in recent New York Heart Association class and clinical presentations (orthopnea, rales, and dyspnea on exertion) between the NLR tertile groups. In terms of laboratory
Discussion
This post hoc analysis of results from the BLAST-AHF, Pre-RELAX-AHF, and RELAX-AHF studies combined database examined the relations between baseline levels of NLR, with the changes in dyspnea to day 5 by VAS AUC, WHF through day 5, 30-day all-cause mortality, 60-day HF/RF rehospitalizations or CV death, and 180-day all-cause mortality, and 180-day CV death. The unadjusted and adjusted analyses suggest that a higher NLR at baseline was not associated with changes in dyspnea to day 5 by VAS AUC.
Disclosures
The BLAST-AHF study was sponsored by Trevena, Inc. The Pre-RELAX-AHF and RELAX-AHF studies were sponsored by Corthera Inc., a Novartis affiliate company. No external support was provided for these analyses. Drs. Davison, Takagi, Edwards, and Cotter are employees of Momentum Research Inc. Momentum Research Inc. has received grants for research from Abbott Laboratories, Amgen, Celyad, Cirius Therapeutics Inc., Corteria Pharmaceuticals, Roche Diagnostics Inc., Sanofi, Windtree Therapeutics Inc.
References (29)
- et al.
Association Between admission neutrophil to lymphocyte ratio and outcomes in patients With acute coronary syndrome
Am J Cardiol
(2008) - et al.
Neutrophil-to-lymphocyte ratio improves outcome prediction of acute intracerebral hemorrhage
J Neurol Sci
(2018) - et al.
Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study
Lancet
(2009) - et al.
RELAXin in Acute Heart Failure (RELAX-AHF) Investigators. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomized, placebo-controlled trial
Lancet
(2013) - et al.
Usefulness of neutrophil-to-lymphocyte ratio in risk stratification of patients with advanced heart failure
Am J Cardiol
(2015) - et al.
Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure
J Am Coll Cardiol
(2007) Myeloperoxidase – A bridge linking inflammation and oxidative stress with cardiovascular disease
Clin Chim Acta
(2019)- et al.
Catecholamine-induced leukocytosis: early observations, current research, and future directions
Brain Behav Immun
(1996) - et al.
Usefulness of neutrophil to lymphocyte ratio in predicting short-and long-term mortality after non-ST-elevation myocardial infarction
Am J Cardiol
(2010) - et al.
The clinical significance of interleukin-6 in heart failure: results from the BIOSTAT-CHF study
Eur J Heart Fail
(2019)
Cytokine mRNA degradation in cardiomyocytes restrains sterile inflammation in pressure-overloaded hearts
Circulation
Innate immunity and the failing heart: the cytokine hypothesis revisited
Circ Res
Importance of prognostic value of neutrophil to lymphocyte ratio in patients with ST-elevation myocardial infarction
Medicine (Balthimore)
Balance between innate versus adaptive immune system and the risk of dementia: A population-based cohort study
J Neuroinflammation
Cited by (10)
Role of β Blockers in Inflammatory Response During Acute Heart Failure
2023, American Journal of CardiologyRole of Beta Blockers in Inflammatory Response During Acute Heart Failure
2023, American Journal of CardiologySoluble ST2 as a possible biomarker for inflammation in patients with acute heart failure
2024, Journal of Cardiovascular MedicineUnraveling the clinical significance and prognostic value of the neutrophil‑to‑lymphocyte ratio, platelet‑to‑lymphocyte ratio, systemic immune‑inflammation index, systemic inflammation response index, and delta neutrophil index: An extensive literature review
2024, Turkish Journal of Emergency MedicineNeutrophil to lymphocyte ratio (NLR) prognostic effects on heart failure; a systematic review and meta-analysis
2023, BMC Cardiovascular Disorders